Company intelligence / Profile preview

Kappa Bioscience

Ownership: Private
Development stage: Other

Overview

Kappa Bioscience is a pioneer in the commercial production of high-purity, all-trans vitamin K2 MK‑7, branded as K2VITAL®, with strong intellectual property and a deep clinical research portfolio. Their products are widely used in dietary supplements for bone, heart, and immune health. The company has launched the first man-made menaquinone‑7 in its natural form and recently introduced an organic-certified version for oil-based applications.

Therapeutic areas: ImmunologyEndocrinologyCardiovascular
Modalities: Small molecule (vitamin)
Industry: Food & Nutrition

Partnerships

Works with global nutritional supplement companies, contract manufacturing organizations (CMOs), distributorspartnered previously with Verdane Edda as investor

Beyond the preview

Go deeper on Kappa Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kappa Bioscience.

Explore the full profile